Danuglipron is a small-molecule GLP-1 agonist, formerly under development by Pfizer that, in an oral formulation, was under investigation as a therapy for diabetes mellitus. From Wikipedia
The pharmaceutical giant shifts focus to early-stage obesity treatments following the latest setback in its weight-loss drug pipeline.
